Guangli Biotechnology Holdings Co., Ltd. 2025 Q4 Financial Report
Guangli Biotechnology Holdings Co., Ltd. reported an operating revenue of 377 million NTD and a net loss after tax of 193 million NTD for Q4 2025, resulting in a basic EPS of -2.07 NTD.
📋 Article Processing Timeline
- 📰 Published: December 1, 2025 at 09:00
- 🔍 Collected: April 7, 2026 at 08:00 (3047h 0m after Published)
- 🤖 AI Analyzed: April 8, 2026 at 00:21 (16h 20m after Collected)
Company Code: 6431, Company Name: Guangli Biotechnology Holdings Co., Ltd., Industry: Biotechnology and Medical Industry, Year/Quarter: 2025 Q4, Basic EPS: -2.07 NTD, Operating Revenue: 377 million NTD, Net Income After Tax: -193 million NTD.